Robert Foster, departing Hepion Pharmaceuticals CEO
December 7, 2023 08:50 AM EST
People
Pharma

NASH drug­mak­er He­p­i­on to seek strate­gic al­ter­na­tives

Kyle LaHucik

Biotech Correspondent

He­p­i­on Phar­ma­ceu­ti­cals said Thurs­day it will seek strate­gic al­ter­na­tives to keep its Phase IIb NASH drug de­vel­op­ment pro­gram alive along­side news …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Up­dat­ed: Oma­da Health rose 21% in its pub­lic mar­ket de­but

Ot­su­ka spells out Phase 3 win in rare kid­ney dis­ease, Ve­ra’s stock takes a hit

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times